← FDA DRUG APPROVALS

FDA ANDA · ANDA208888

DOXORUBICIN HYDROCHLORIDE

doxorubicin

Sponsor: AMNEAL

APPLICATION
ANDA208888
TYPE
ANDA
ORIGINAL APPROVAL
2017-02-17
LATEST ACTION
2023-07-12
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

DOXORUBICIN HYDROCHLORIDEPrescription
DOXORUBICIN HYDROCHLORIDE 20MG/VIAL · INJECTABLE · INJECTION
DOXORUBICIN HYDROCHLORIDEPrescription
DOXORUBICIN HYDROCHLORIDE 50MG/VIAL · INJECTABLE · INJECTION

Approval history

2023-07-12Labeling · Supplement 3 · standardAP
2023-07-12Labeling · Supplement 2 · standardAP
2017-02-17UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →